Ascletis Advances Oral Obesity Drug Combination with Superior Weight Loss Data — Ascletis Pharma Inc.

Event summary

Ascletis selected ASC30_48 FDC, a fixed-dose combination of oral GLP-1R and GIPR agonists, for clinical development.
ASC30_48 demonstrated 52% greater weight loss than ASC30 monotherapy in NHP studies.
IND application submission expected Q4 2026 for the once-daily oral obesity treatment.
ASC48 shows higher potency (EC50 = 1 pM) than tirzepatide (EC50 = 3 pM).
Company leveraged AI-assisted drug discovery technology to develop ASC48.

The big picture

Ascletis is positioning itself in the competitive obesity treatment market with an oral alternative to dominant injectable therapies. The company's AI-assisted drug discovery approach and focus on once-daily administration could differentiate its offering, but must overcome significant regulatory and clinical hurdles to challenge established players like tirzepatide.

What we're watching

Regulatory Approval: Whether the FDA will accept the IND application and allow clinical trials to proceed as planned in Q4 2026.
Clinical Performance: How ASC30_48 FDC performs in human trials compared to its superior NHP study results, particularly against tirzepatide's established efficacy profile.
Market Differentiation: The pace at which Ascletis can position this oral combination therapy as a viable alternative to injectable obesity treatments like tirzepatide.